Aligos Therapeutics

Aligos is a preclinical stage biotechnology company that researches and develops novel therapies for hepatologic diseases and viral infections. Read more

2 Followers on Owler
2 Followers on Owler
2 Followers on Owler
2 Followers on Owler

Aligos Therapeutics

Aligos is a preclinical stage biotechnology company that researches and develops novel therapies for hepatologic diseases and viral infections. Read more

Lawrence M. Blatt's photo - Co-Founder & CEO of Aligos Therapeutics

Co-Founder & CEO

Lawrence M. Blatt

CEO Approval Rating

90/100

Founded:

2018

Status:

PublicIndependent CompanyNASDAQALGS

ALIGOS THERAPEUTICS TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

NorthSea Therapeutics is one of Aligos Therapeutics's top competitors. NorthSea Therapeutics was founded in 2017 in Naarden, Noord-Holland. Like Aligos Therapeutics, NorthSea Therapeutics also operates in the Biotechnology industry. NorthSea Therapeutics generates $4M more revenue than Aligos Therapeutics.

Metacrine is a top competitor of Aligos Therapeutics. Metacrine was founded in 2014, and is headquartered in San Diego, California. Like Aligos Therapeutics, Metacrine also competes in the Biotechnology field. Metacrine generates $1.4M more revenue vs. Aligos Therapeutics.

Nimbus Therapeutics is seen as one of Aligos Therapeutics's top competitors. Nimbus Therapeutics is headquartered in Cambridge, Massachusetts, and was founded in 2009. Like Aligos Therapeutics, Nimbus Therapeutics also operates in the Pharmaceuticals field. Nimbus Therapeutics generates ∞% the revenue of Aligos Therapeutics.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Apple a competitor of Aligos Therapeutics?

Aligos Therapeutics Quarterly and Annual Revenue

Coming soon for Aligos Therapeutics!

Annual Revenue

Aligos Therapeutics Acquisitions

No recent acquisitions found related to Aligos Therapeutics

Aligos Therapeutics Funding History

$100M$375M

Since Aligos Therapeutics was founded in 2018, it has participated in 3 rounds of funding. In total Aligos Therapeutics has raised $375.0M. Aligos Therapeutics' last funding round was on Oct 2020 for a total of $150.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

IPO
Oct 2020
$150M

Series B
Jan 2020
$125M
Series A
Nov 2018
$100M

Since Aligos Therapeutics was founded in 2018, it has participated in 3 rounds of funding. In total Aligos Therapeutics has raised $375.0M. Aligos Therapeutics' last funding round was on Oct 2020 for a total of $150.0M

Aligos Therapeutics Investments

No recent investments found related to Aligos Therapeutics

Aligos Therapeutics News

December 8, 2020Zacks

Aligos (ALGS) Inks Collaboration With Merck for NASH Therapy

Aligos (ALGS) signs an exclusive research collaboration agreement with Merck to discover and develop ... See more »
November 16, 2020MarketScreener

Aligos Therapeutics Presents Data on Chronic Hepatitis B, NASH and Hepatocellular Carcinoma Programs at AASLD's The Liver Meeting Digital Experience 2020

(marketscreener.com) SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 -- Aligos Therapeutics, Inc. , a clin... See more »
October 20, 2020Global Legal Chronicle

Aligos Therapeutics' $150 Million Initial Public Offering

Latham & Watkins LLP represented Aligos Therapeutics, Inc. in the transaction. Aligos Therapeutics, I... See more »
October 17, 2020FinanzNachrichten

Aligos Therapeutics Prices IPO Of 10 Mln Shares At $15/Shr

WASHINGTON (dpa-AFX) - Aligos Therapeutics, Inc. announced that it has priced initial public offering... See more »
October 16, 2020Venture Capital Journal

VC-backed Aligos Therapeutics goes public

Aligos Therapeutics, a biopharmaceutical company focused on treating viral infections and liver disea... See more »
October 16, 2020The Business Journals: San Jose

Bay Area's Eargo, Aligos Therapeutics raise $291M in IPOs

Their IPOs bring the total for Bay Area companies that have gone public this year up to 42, a new pos... See more »

Aligos Therapeutics Press Releases

November 12, 2020GlobeNewswire

Aligos Therapeutics is awarded 1.8M VLAIO grant to advance chronic hepatitis B research

SOUTH SAN FRANCISCO, Calif. and LEUVEN, Belgium, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutic... See more »
June 3, 2020StreetInsider

Aligos Therapeutics Appoints Lesley Ann Calhoun as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Aligos), a ... See more »

Social Media

Aligos Therapeutics Headquarters

1 Corporate Drive 2nd Floor

San Francisco, California94080

Driving Directions »

Trending Companies

Aligos Therapeutics Summary

ABOUT

Overview

Aligos is a preclinical stage biotechnology company that researches and develops novel therapies for hepatologic diseases and viral infections. Aligos Therapeutics was founded in 2018. Aligos Therapeutics' headquarters is located in San Francisco, Cal...

CEO

Aligos Therapeutics's Co-Founder & CEO, Lawrence M. Blatt, currently has an approval rating of 90%. Aligos Therapeutics's primary competitors are NorthSea Therapeutics, Metacrine & Nimbus Therapeutics.

Website

aligos.com

Frequently Asked Questions about Aligos Therapeutics

  1. When was Aligos Therapeutics founded?

    Aligos Therapeutics was founded in 2018
  2. Who is Aligos Therapeutics's CEO?

    Aligos Therapeutics's CEO is Lawrence M. Blatt
  3. How much revenue does Aligos Therapeutics generate?

    Aligos Therapeutics generates $ < 1M in revenue
  4. How much funding does Aligos Therapeutics have?

    Aligos Therapeutics has historically raised $375M in funding
  1. Where is Aligos Therapeutics's headquarters?

    Aligos Therapeutics's headquarters is in San Francisco California, USA
  2. How many employees does Aligos Therapeutics have?

    Aligos Therapeutics has 73 employees
  3. What sector does Aligos Therapeutics operate in?

    Aligos Therapeutics is in Pharmaceuticals, Biotechnology
  4. Who are Aligos Therapeutics's competitors?

    Aligos Therapeutics's top competitors are NorthSea Therapeutics, Metacrine, Nimbus Therapeutics